6747 Stock Overview
Brighten Optix Corporation researches and develops, manufactures, and sells specialty contact lenses in Taiwan and the Asia Pacific region.
Brighten Optix Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$192.00|
|52 Week High||NT$479.50|
|52 Week Low||NT$190.00|
|1 Month Change||-10.49%|
|3 Month Change||-12.73%|
|1 Year Change||-43.53%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||50.01%|
Recent News & Updates
|6747||TW Medical Equipment||TW Market|
Return vs Industry: 6747 underperformed the TW Medical Equipment industry which returned -8.3% over the past year.
Return vs Market: 6747 underperformed the TW Market which returned -18% over the past year.
|6747 Average Weekly Movement||2.7%|
|Medical Equipment Industry Average Movement||5.4%|
|Market Average Movement||5.1%|
|10% most volatile stocks in TW Market||8.3%|
|10% least volatile stocks in TW Market||2.4%|
Stable Share Price: 6747 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 6747's weekly volatility (3%) has been stable over the past year.
About the Company
Brighten Optix Corporation researches and develops, manufactures, and sells specialty contact lenses in Taiwan and the Asia Pacific region. The company offers hard contact lenses under HiClear and Soclear brands; soft contact lenses under Brio+moist, iDealsoft, and MyOKvision names; contact lens care potion under the Oxy vision plus Briomoist and Mu likang brands; and other ancillary products, as well as night-wear orthokeratology hard contact lenses. Brighten Optix Corporation is based in Taipei, Taiwan.
Brighten Optix Fundamentals Summary
|6747 fundamental statistics|
Is 6747 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6747 income statement (TTM)|
|Cost of Revenue||NT$228.37m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||9.99|
|Net Profit Margin||33.73%|
How did 6747 perform over the long term?See historical performance and comparison
4.5%Current Dividend Yield
Is 6747 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6747?
Other financial metrics that can be useful for relative valuation.
|What is 6747's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 6747's PE Ratio compare to its peers?
|6747 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
4126 Pacific Hospital Supply
1786 SciVision Biotech
6612 ICARES Medicus
6747 Brighten Optix
Price-To-Earnings vs Peers: 6747 is good value based on its Price-To-Earnings Ratio (19.2x) compared to the peer average (25.3x).
Price to Earnings Ratio vs Industry
How does 6747's PE Ratio compare vs other companies in the TW Medical Equipment Industry?
Price-To-Earnings vs Industry: 6747 is expensive based on its Price-To-Earnings Ratio (19.2x) compared to the TW Medical Equipment industry average (18.9x)
Price to Earnings Ratio vs Fair Ratio
What is 6747's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||19.2x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6747's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 6747 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6747 (NT$192) is trading below our estimate of fair value (NT$234.92)
Significantly Below Fair Value: 6747 is trading below fair value, but not by a significant amount.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Brighten Optix forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 6747's forecast earnings growth is above the savings rate (0.7%).
Earnings vs Market: Insufficient data to determine if 6747's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 6747's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 6747's revenue (20.9% per year) is forecast to grow faster than the TW market (7.7% per year).
High Growth Revenue: 6747's revenue (20.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6747's Return on Equity is forecast to be low in 3 years time (19.1%).
Discover growth companies
How has Brighten Optix performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6747 has a high level of non-cash earnings.
Growing Profit Margin: 6747's current net profit margins (33.7%) are lower than last year (36.5%).
Past Earnings Growth Analysis
Earnings Trend: 6747's earnings have grown significantly by 32.7% per year over the past 5 years.
Accelerating Growth: 6747's earnings growth over the past year (6.3%) is below its 5-year average (32.7% per year).
Earnings vs Industry: 6747 earnings growth over the past year (6.3%) underperformed the Medical Equipment industry 19%.
Return on Equity
High ROE: 6747's Return on Equity (21.6%) is considered high.
Discover strong past performing companies
How is Brighten Optix's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 6747's short term assets (NT$948.9M) exceed its short term liabilities (NT$328.2M).
Long Term Liabilities: 6747's short term assets (NT$948.9M) exceed its long term liabilities (NT$44.6M).
Debt to Equity History and Analysis
Debt Level: 6747 is debt free.
Reducing Debt: 6747 has no debt compared to 5 years ago when its debt to equity ratio was 49.8%.
Debt Coverage: 6747 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 6747 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Brighten Optix current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|Brighten Optix Dividend Yield vs Market|
|Company (Brighten Optix)||4.5%|
|Market Bottom 25% (TW)||2.6%|
|Market Top 25% (TW)||7.0%|
|Industry Average (Medical Equipment)||3.9%|
|Analyst forecast in 3 Years (Brighten Optix)||5.7%|
Notable Dividend: 6747's dividend (4.52%) is higher than the bottom 25% of dividend payers in the TW market (2.59%).
High Dividend: 6747's dividend (4.52%) is low compared to the top 25% of dividend payers in the TW market (7%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 6747 has been paying a dividend for less than 10 years.
Growing Dividend: 6747's dividend payments have increased, but the company has only paid a dividend for 2 years.
Earnings Payout to Shareholders
Earnings Coverage: At its current payout ratio (86.9%), 6747's payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (121.5%), 6747's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Brighten Optix has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Brighten Optix Corporation's employee growth, exchange listings and data sources
- Name: Brighten Optix Corporation
- Ticker: 6747
- Exchange: TPEX
- Founded: NaN
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: NT$4.644b
- Shares outstanding: 24.19m
- Website: https://www.brightenoptix.com.tw
- Brighten Optix Corporation
- No.150, Chengde Road
- 6th Floor-1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|6747||TPEX (Taipei Exchange)||Yes||Ordinary Shares||TW||TWD||Oct 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/01 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.